Table 1 The clinical information of CMML patients classified as MD/MP subtypes
From: Mutational landscape of chronic myelomonocytic leukemia in Chinese patients
Variables | Total CMML (n = 178) | MD-CMML (n = 83) | MP-CMML (n = 95) | P value |
|---|---|---|---|---|
Age in years; median (range) | 62 (17–90) | 63 (24–90) | 60 (17–85) | 0.362 |
Sex (male); n (%) | 118 (66.3%) | 54 (65.1%) | 64 (67.4%) | 0.745 |
Hemoglobin g/L; median (range) | 85 (38–173) | 85 (38–140) | 87 (40–173) | 0.410 |
ANC ×109/L; median (range) | 4.75 (0.45–29.97) | 2.17 (0.45–6.15) | 10.9 (1.14–29.97) | 0.000 |
AMC ×109/L; median (range) | 2.43 (1.01–16.32) | 1.8 (1.01–5.69) | 3.23 (1.11–16.32) | 0.002 |
Platelets×109/L; median (range) | 76 (3–977) | 69 (11–900) | 85 (3–977) | 0.828 |
LDH IU/ml; median (range) | 279.1 (120–1403) | 224.6 (120–977.1) | 333.5 (152.4–1403) | 0.008 |
Cytogenetic risk groupa n (%) | 0.032 | |||
 Low-risk | 129 (72.5%) | 66 (79.5%) | 63 (66.3%) | 0.049 |
 Intermediate-risk | 18 (10.1%) | 9 (10.8%) | 9 (9.5%) | 0.762 |
 High-risk | 31 (17.4%) | 8 (9.7%) | 23 (24.2%) | 0.011 |
Splenomegaly ; n (%) | 42 (28.4%) | 13 (19.6%) | 29 (35.3%) | 0.036 |
Treatment strategy; n (%) | 0.821 | |||
 Best supportive care | 28 (30.4%) | 12 (28.6%) | 16 (32.0%) |  |
 HMAs ± chemotherapy/allo-HSCT | 64 (69.6%) | 30 (71.4%) | 34 (68.0%) |  |